Aurealis Therapeutics AG Revenue and Competitors

Kuopio,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aurealis Therapeutics AG's estimated annual revenue is currently $3.4M per year.(i)
  • Aurealis Therapeutics AG's estimated revenue per employee is $155,000

Employee Data

  • Aurealis Therapeutics AG has 22 Employees.(i)
  • Aurealis Therapeutics AG grew their employee count by 0% last year.

Aurealis Therapeutics AG's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head Pre-Clinical & PharmacologyReveal Email/Phone
3
Head Quality and Regulatory AffairsReveal Email/Phone
4
Director Microbiology, Genetic Engineering and FermentationReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
Chief Operating OfficerReveal Email/Phone
7
Clinical Project ManagerReveal Email/Phone
8
Senior Clinical Project ManagerReveal Email/Phone
9
Clinical Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Aurealis Therapeutics AG?

Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The genetically modified lactic acid bacteria based therapy is designed to improve the quality of life for patients who requires tissue generation for example with diabetic foot ulcer. This is remarkable advancement for people who generally have only had access to medicines that treat symptoms versus promote tissue regeneration itself.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aurealis Therapeutics AG News

2022-04-06 - Global Venous Leg Ulcers (Crural ulcer) Drugs Development Research Report 2022: Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology) by ... Aurealis Therapeutics AG.

2022-02-22 - Asia Deal Watch: SV Investment And Orange Grove Will Team Up ...

Pfizer Inc. Sandoz Pharma Ltd. Biocon, Ltd. Fresenius Kabi AG · Aurobindo Pharma Limited · Zydus Cadila · Aurealis Therapeutics · Xbiome Co.,...

2022-02-22 - Aurealis Therapeutics and Xbiome Enter into a License and ...

Aurealis Therapeutics AG is a Swiss-Finnish private clinical stage synthetic biology company focusing on development of lactic acid bacteria...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.5M2514%N/A
#2
$5.3M30-23%N/A
#3
N/A3559%N/A
#4
$8.4M390%N/A
#5
$12.7M6724%N/A